Study of V117957 in Overactive Bladder Syndrome
Completed · Phase 1 · Has a placebo group
Conditions studied: Overactive Bladder Syndrome
In brief
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
Key facts
- Study ID
- NCT06024642
- Run by
- Imbrium Therapeutics
- People needed
- 51
- Starts
- 2022-06-30
- Expected to finish
- 2024-05-21
- Last updated by the study team
- 2025-06-26
Who can join
Age: 18 and older, up to 70. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Arizona Urology Specialists, PLLC — Tucson, Arizona, United States
- Hope Clinical Research, LLC — Canoga Park, California, United States
- ARK Clinical Research — Long Beach, California, United States
- Urology Group of Southern California — Los Angeles, California, United States
- Providea Health Partners, LLC — Evergreen Park, Illinois, United States
- DelRicht Research — New Orleans, Louisiana, United States
- Ochsner LSU Health Shreveport - Regional Urology — Shreveport, Louisiana, United States
- Boston Clinical Trials — Boston, Massachusetts, United States
- Bay State Clinical Trials, Inc. — Watertown, Massachusetts, United States
- AccuMed Research Associates — Garden City, New York, United States
- Unified Women's Clinical Research-Lyndhurst — Winston-Salem, North Carolina, United States
- The Clinical Trial Center, LLC — Jenkintown, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.